Ophthalmics Pipeline

At Eluminex Ophthalmics, our mission is to create the next generation of protein therapeutics for vision-threatening diseases and will be the first company to enter the clinic with a novel tri-specific antibody in 2024.

We have developed a proprietary pipeline of tri-specific humanized antibodies for the intravitreal treatment of retinal disease, a bi-specific systemically administered antibody for thyroid eye disease (TED) and are developing new collagen-based treatments for corneal disease as an alternative to the global shortage of cadaveric corneal allografts.

  • Discovery
  • Preclinical
  • IND
  • Phase 1
  • Phase 2
  • Phase 3

EB-301:

Biosynthetic cornea
Corneal blindness

EB-105:

Tri-specific antibody
Diabetic macular edema

EB-107:

Tri-specific antibody
Retinal disease

EB-110:

Tri-specific antibody
Retinal disease

EB-401:

Bi-specific antibody
Thyroid eye disease

EB-105
Tri-specific Antibody; Diabetic Macular Edema; IND

EB-105 contains functional units for inhibition of multiple clinically validated factors that contribute to vascular leakage, angiogenesis, and retinal inflammation. The first indication of EB-105 is diabetic macular edema (DME). Eluminex has completed all pre-clinical pharmacology studies, CMC development, and is currently conducting IND-enabling pre-clinical studies to support the first-in-human clinical trial in patients in the United States with DME in Q2 2024. EB-105 is wholly developed and owned by Eluminex Biosciences.

EB-107
Tri-specific Antibody; Retinal Disease; Pre-IND

EB-107 contains functional units for inhibition of multiple factors that contribute to vascular leakage, angiogenesis, retinal inflammation and fibrosis. The first indication of EB-107 is wet AMD. Eluminex has completed all pre-clinical pharmacology studies and ready to proceed to CMC development. EB-107 is wholly developed and owned by Eluminex Biosciences.

EB-110
Tri-specific Antibody; Retinal Disease; Pre-IND

EB-110 contains functional units for inhibition of multiple angiogenic factors to treat retinal vascular diseases in patients who showed sub-optimal or no response to previous anti-VEGF therapies. Eluminex has completed all pre-clinical pharmacology studies of EB-110 and ready to proceed to CMC development. EB-110 is wholly developed and owned by Eluminex Biosciences.

EB-401
Bi-specific Antibody; Thyroid Eye Disease; Pre-IND

EB-401 is a humanized bi-specific fusion antibody designed to inhibit two clinically validated factors that play important roles in the pathogenesis of thyroid eye disease (TED). Eluminex has completed all pre-clinical pharmacology studies and is ready to proceed to CMC development. EB-401 is wholly developed and owned by Eluminex Biosciences.

EB-301
Full Length Triple Helix rhCIII;  Corneal Blindness; Phase 3

EB-301 is a novel clinical stage first-in-class biosynthetic cornea derived from full-length, triple helix recombinant human Type III collagen (rhCIII) and is in mid-stage clinical development initially for the China market. EB-301 is intended for the treatment of visual acuity deficits associated with corneal blindness due to stable, non-infectious stromal lesions amenable to anterior lamellar keratoplasty (ALK) as an alternative to cadaveric human donor cornea.